Oasmia Pharmaceutical Stock Price, News & Analysis (NASDAQ:OASM)

$1.00 0.01 (1.01 %)
(As of 12/10/2017 04:00 PM ET)
Previous Close$1.00
Today's Range$0.86 - $1.00
52-Week Range$0.80 - $3.70
VolumeN/A
Average Volume4,032 shs
Market Capitalization$58.80 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Oasmia Pharmaceutical (NASDAQ:OASM)

Oasmia Pharmaceutical AB (publ) develops, produces, markets, and sells drugs for human and veterinary oncology primarily in Sweden. It focuses on manufacturing formulations based on cytostatics. The company’s approved products include Paccal Vet-CA1 for the treatment of mammary carcinoma and squamous cell carcinoma in dogs; and Paclical for the treatment of ovarian cancer. It is also developing Paclical for the treatment of metastatic breast cancer; Doxophos, a formulation of the cytostatic doxorubicin, for the treatment of breast cancer; Docecal, a patented formulation of cytostatic docetaxel, for the treatment of breast cancer; and OAS-19 to treat various cancers. Its product candidates for animal health comprise Paccal Vet, a formulation of paclitaxel, for the treatment of mastocytoma in dogs; and Doxophos Vet for the treatment of lymphoma in dogs. Oasmia Pharmaceutical AB was founded in 1990 and is based in Uppsala, Sweden.

Receive OASM News and Ratings via Email

Sign-up to receive the latest news and ratings for OASM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:OASM
CUSIPN/A
Phone461-850-5440

Debt

Debt-to-Equity RatioN/A
Current Ratio0.69%
Quick Ratio0.63%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$20,000.00
Price / Sales2,101.50
Cash FlowN/A
Price / CashN/A
Book Value$0.82 per share
Price / Book1.22

Profitability

Trailing EPSN/A
Net Income$-18,330,000.00
Net Margins-99,066.66%
Return on Equity-47.53%
Return on Assets-28.43%

Miscellaneous

Employees66
Outstanding Shares42,030,000

Oasmia Pharmaceutical (NASDAQ:OASM) Frequently Asked Questions

What is Oasmia Pharmaceutical's stock symbol?

Oasmia Pharmaceutical trades on the NASDAQ under the ticker symbol "OASM."

How often does Oasmia Pharmaceutical pay dividends? What is the dividend yield for Oasmia Pharmaceutical?

Oasmia Pharmaceutical announced a ... dividend on Tuesday, July 11th. Investors of record on Monday, July 17th will be paid a dividend of $0.0185 per share on Monday, July 24th. The ex-dividend date of this dividend is Thursday, July 13th. View Oasmia Pharmaceutical's Dividend History.

When will Oasmia Pharmaceutical make its next earnings announcement?

Oasmia Pharmaceutical is scheduled to release their next quarterly earnings announcement on Friday, December, 15th 2017. View Earnings Estimates for Oasmia Pharmaceutical.

Who are some of Oasmia Pharmaceutical's key competitors?

How do I buy Oasmia Pharmaceutical stock?

Shares of Oasmia Pharmaceutical can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Oasmia Pharmaceutical's stock price today?

One share of Oasmia Pharmaceutical stock can currently be purchased for approximately $1.00.

How big of a company is Oasmia Pharmaceutical?

Oasmia Pharmaceutical has a market capitalization of $58.80 million and generates $20,000.00 in revenue each year. Oasmia Pharmaceutical employs 66 workers across the globe.

How can I contact Oasmia Pharmaceutical?

Oasmia Pharmaceutical's mailing address is Vallongatan 1, Uppsala V7, 75228. The company can be reached via phone at 461-850-5440 or via email at [email protected]


MarketBeat Community Rating for Oasmia Pharmaceutical (OASM)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  43 (Vote Outperform)
Underperform Votes:  38 (Vote Underperform)
Total Votes:  81
MarketBeat's community ratings are surveys of what our community members think about Oasmia Pharmaceutical and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Oasmia Pharmaceutical (NASDAQ:OASM) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $6.00$6.00$6.00$6.00
Price Target Upside: 69.97% upside69.97% upside69.97% upside69.97% upside

Oasmia Pharmaceutical (NASDAQ:OASM) Consensus Price Target History

Price Target History for Oasmia Pharmaceutical (NASDAQ:OASM)

Oasmia Pharmaceutical (NASDAQ:OASM) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/12/2016HC WainwrightInitiated CoverageBuy$6.00N/AView Rating Details
9/12/2016Rodman & RenshawInitiated CoverageBuy$6.00 -> $6.00N/AView Rating Details
(Data available from 12/10/2015 forward)

Earnings

Earnings History for Oasmia Pharmaceutical (NASDAQ:OASM)


No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Oasmia Pharmaceutical (NASDAQ:OASM) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Oasmia Pharmaceutical (NASDAQ:OASM) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/11/2017...$0.027/13/20177/17/20177/24/2017
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Oasmia Pharmaceutical (NASDAQ OASM)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Oasmia Pharmaceutical (NASDAQ OASM) News Headlines

Source:
DateHeadline
Oasmia Pharmaceutical (OASM) Lifted to Sell at ValuEngineOasmia Pharmaceutical (OASM) Lifted to Sell at ValuEngine
www.americanbankingnews.com - December 9 at 11:26 AM
Oasmia Pharmaceutical AB :OASM-US: Earnings Analysis: Q2, 2018 By the Numbers : December 6, 2017Oasmia Pharmaceutical AB :OASM-US: Earnings Analysis: Q2, 2018 By the Numbers : December 6, 2017
finance.yahoo.com - December 6 at 10:26 AM
BRIEF-Oasmia Pharmaceutical Q2 operating loss shrinksBRIEF-Oasmia Pharmaceutical Q2 operating loss shrinks
www.reuters.com - December 1 at 5:28 PM
BRIEF-Oasmia CFO resignsBRIEF-Oasmia CFO resigns
www.reuters.com - October 5 at 6:22 PM
Oasmia Pharma finance chief departs; shares down 6% premarketOasmia Pharma finance chief departs; shares down 6% premarket
seekingalpha.com - October 5 at 6:22 PM
Oasmia Pharmaceutical AB Announces Resignation of its Chief Financial OfficerOasmia Pharmaceutical AB Announces Resignation of its Chief Financial Officer
www.globenewswire.com - October 5 at 6:22 PM
Oasmia Pharmaceutical AB :OASM-US: Earnings Analysis: Q1, 2018 By the Numbers : September 18, 2017Oasmia Pharmaceutical AB :OASM-US: Earnings Analysis: Q1, 2018 By the Numbers : September 18, 2017
finance.yahoo.com - September 19 at 6:08 AM
Notification from Oasmia Pharmaceutical ABNotification from Oasmia Pharmaceutical AB
globenewswire.com - September 12 at 7:41 AM
Oasmia Pharmaceutical receives market approval for its Anti-Cancer Drug Doxophos® in RussiaOasmia Pharmaceutical receives market approval for its Anti-Cancer Drug Doxophos® in Russia
feeds.benzinga.com - August 8 at 8:07 AM
Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ)Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ)
globenewswire.com - July 31 at 11:48 PM
Oasmia Pharmaceutical AB :OASM-US: Earnings Analysis: Q4, 2017 By the Numbers : July 12, 2017Oasmia Pharmaceutical AB :OASM-US: Earnings Analysis: Q4, 2017 By the Numbers : July 12, 2017
finance.yahoo.com - July 13 at 7:33 AM
Oasmia Pharmaceutical AB (OASM) Announces $0.02 ... DividendOasmia Pharmaceutical AB (OASM) Announces $0.02 ... Dividend
www.americanbankingnews.com - July 11 at 4:28 PM
Oasmia Pharmaceutical AB (publ) announces result of the rights issueOasmia Pharmaceutical AB (publ) announces result of the rights issue
globenewswire.com - July 9 at 7:41 PM
The Oasmia Pharmaceutical Annual Report is now publishedThe Oasmia Pharmaceutical Annual Report is now published
globenewswire.com - July 7 at 7:48 AM
BRIEF-Oasmia enters into marketing, distribution agreement concerning Russia, other marketsBRIEF-Oasmia enters into marketing, distribution agreement concerning Russia, other markets
www.reuters.com - June 14 at 4:24 PM
Oasmia Pharma (OASM) Announces New Exclusive Marketing/Distribution Deal with Hetero Group for Russia & Other CIS MarketsOasmia Pharma (OASM) Announces New Exclusive Marketing/Distribution Deal with Hetero Group for Russia & Other CIS Markets
www.streetinsider.com - June 14 at 4:24 PM
Oasmia Pharma initiates equity offering, preferential right to current shareholdersOasmia Pharma initiates equity offering, preferential right to current shareholders
seekingalpha.com - June 13 at 7:04 PM
Oasmia Pharmaceutical AB (publ): The board of directors resolves upon a rights issue of approximately 163.9 MSEKOasmia Pharmaceutical AB (publ): The board of directors resolves upon a rights issue of approximately 163.9 MSEK
globenewswire.com - June 12 at 8:45 AM
8:03 pm Oasmia Pharmaceutical Chairman Anders Lnner resigns8:03 pm Oasmia Pharmaceutical Chairman Anders Lnner resigns
us.rd.yahoo.com - March 2 at 8:56 AM
BRIEF-Oasmia Pharma reports positive results from study on weekly administration of ApealeaBRIEF-Oasmia Pharma reports positive results from study on weekly administration of Apealea
www.reuters.com - December 22 at 12:50 AM
Oasmia Buys Swedish Cancer Drug for $2.8M (OASM)Oasmia Buys Swedish Cancer Drug for $2.8M (OASM)
www.investopedia.com - October 26 at 6:37 PM
Oasmia Buys Estrogen Receptor Cancer Drug (OASM)Oasmia Buys Estrogen Receptor Cancer Drug (OASM)
www.investopedia.com - October 26 at 6:37 PM
BMYs Opdivo At The Altar Again, MRK Gets FDA Nod, Watch Out For OASMBMY's Opdivo At The Altar Again, MRK Gets FDA Nod, Watch Out For OASM
www.rttnews.com - October 25 at 6:34 PM
BRIEF-Oasmia enters into collaboration agreement for novel cancer projectBRIEF-Oasmia enters into collaboration agreement for novel cancer project
www.reuters.com - October 25 at 11:43 AM
Oasmia Pharma (OASM) Says Its in Discussions on Acquisition of Novel Cancer ProjectOasmia Pharma (OASM) Says It's in Discussions on Acquisition of Novel Cancer Project
www.streetinsider.com - October 22 at 6:04 PM
10 Analyst Stock Picks Under $10 for Massive Upside10 Analyst Stock Picks Under $10 for Massive Upside
247wallst.com - September 18 at 10:48 AM
BRIEF-Oasmia names Fredrik Gynnerstedt as new Chief Financial OfficerBRIEF-Oasmia names Fredrik Gynnerstedt as new Chief Financial Officer
www.reuters.com - September 1 at 6:32 PM
New finance chief at Oasmia PharmaNew finance chief at Oasmia Pharma
seekingalpha.com - September 1 at 6:32 PM
Oasmia Pharma Names Fredrik Gynnerstedt CFO, Effective Dec. 1Oasmia Pharma Names Fredrik Gynnerstedt CFO, Effective Dec. 1
www.rttnews.com - September 1 at 6:32 PM

SEC Filings

Oasmia Pharmaceutical (NASDAQ:OASM) SEC Filings

DateFilerForm TypeView

Social Media

Financials

Oasmia Pharmaceutical (NASDAQ:OASM) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Oasmia Pharmaceutical (NASDAQ OASM) Stock Chart for Sunday, December, 10, 2017

Loading chart…

This page was last updated on 12/10/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.